Seastar Medical Holding Corp. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Seastar Medical Holding Corp. on February 9, 2023. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in Denver, Colorado. Its common stock and warrants trade on The Nasdaq Stock Market LLC under the symbols ICU and ICUCW, respectively.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a regulatory event rather than financial performance data.
Material Changes
On February 9, 2023, the U.S. Food and Drug Administration (FDA) approved the Company's investigational device exemption (IDE) application. This approval permits the Company to conduct a pivotal study evaluating the effectiveness of its Selective Cytopheretic Device (SCD) in reducing hyperinflammation in adults with acute kidney injury (AKI) requiring continuous kidney replacement therapy (CKRT).
Outlook, Risks, and Management Commentary
Management announced the FDA approval via a press release filed as Exhibit 99.1. The filing does not contain specific financial guidance, risk factors, or contingencies beyond the standard regulatory context of conducting a pivotal clinical study.
Investor Verification Checklist
- Verify the specific inclusion and exclusion criteria for the pivotal study on the SCD device.
- Review the full text of the press release (Exhibit 99.1) for details on the study timeline and endpoints.
- Confirm the Company's current cash runway to fund the upcoming pivotal study.
- Monitor future filings for enrollment updates and interim data from the AKI study.